Lymphocyte and immune cell surface antigens (CD antigens)

Lymphocyte and immune cell surface antigens refer to a broad category of proteins, primarily the Cluster of Differentiation (CD) markers, expressed on the plasma membranes of various immune cells such as T cells, B cells, and NK cells (Zola et al., 2007). These molecules are essential for the orchestration of the immune response, facilitating critical processes such as antigen recognition, lymphocyte activation, and trafficking between tissues (Janeway et al., 2001). In clinical medicine, these antigens are pivotal for immunophenotyping and serve as the foundation for targeted therapies in oncology and immunology. For instance, targeting CD20 on B cells is a standard approach for treating certain lymphomas, while targeting checkpoint receptors like PD-1 or CTLA-4 has revolutionized cancer treatment by enhancing T-cell mediated anti-tumor activity (Pardoll, 2012). Because this term encompasses hundreds of distinct proteins with varying structures and functions, it is considered a functional classification category rather than a specific, single therapeutic target (Engel et al., 2015).

Other names

Cluster of DifferentiationCD markersLeukocyte surface antigensImmune cell surface markersLymphocyte surface receptors

Drugs targeting these antigens function through diverse mechanisms including antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), checkpoint inhibition to restore T-cell activity, and direct induction of apoptosis or signal blockade (Pardoll, 2012; Maloney et al., 1997).